Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028694 | 0.94 | KMT2A (0.51) | KMT2ASMN1; SMN2MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL20028491 | 0.90 | KMT2A (0.51) | KMT2ASMN1; SMN2MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL18231857 | 0.90 | KMT2A (0.47) | KMT2ASMN1; SMN2MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL29641667 | 0.90 | KMT2A (0.47) | KMT2ASMN1; SMN2MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL20027768 | 0.88 | MAPT (0.52) | KMT2AMAPTL3MBTL1ALDH1A1TP53 | |
| SCHEMBL20028050 | 0.86 | KMT2A (0.52) | KMT2ASMN1; SMN2MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL20028524 | 0.86 | KMT2A (0.60) | KMT2AMAPTL3MBTL1ALDH1A1MAPK14 | |
| SCHEMBL22897252 | 0.86 | MAPT (0.50) | KMT2ASMN1; SMN2MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL20027787 | 0.85 | KMT2A (0.51) | KMT2ASMN1; SMN2MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL20028223 | 0.84 | KMT2A (0.53) | KMT2ASMN1; SMN2MAPTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | KMT2A 4418/4885SMN1; SMN2 200/4885MAPT 562/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | KMT2A 4469/4885SMN1; SMN2 263/4885MAPT 330/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | KMT2A 4418/4885SMN1; SMN2 200/4885MAPT 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.